Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Biologics Contract Manufacturing Market Dynamics, Forecast, Analysis and Supply Demand 2017-2027

Author: Amir Shaikh
by Amir Shaikh
Posted: Nov 24, 2018

Biologics are genetically engineered proteins which originate from human genes. These drugs target the specific parts of the immune system. Biologics are entirely different from chemically synthesized drugs. There is wide range of biologics products include vaccines, blood components, allergenic, somatic cells, gene therapy and recombinant therapeutic proteins. Biologics are constituted as nucleic acids or proteins or may be cells and tissue from living entities. Biologics are isolated from different sources such as animal, human or microbes by using different biotechnological methods. Biologics are a complex mixture, and it is heat sensitive product and highly susceptible to microbial contamination. Therefore manufacturing of biologics needs very aseptic environment and skilled professional. Hence, the demand for biologic contract manufacturing has shown subsequent growth. The pharmaceutical companies are signing an agreement with CMO’s for the manufacturing of biologics.

Biologics Contract Manufacturing Market: Drivers and Restraints

The factors driving the growth of biologics contract manufacturing are growing number of drug development by traditional pharmaceutical companies and the entrance of various small manufacturers in the pharmaceutical market. Increasing rate of drug approval by FDA and number drugs in the pipeline has also boosted the growth of biologic contract manufacturing market. Increase in generic drugs competition and rise in patent expiry has also propelled the growth of biologics contract manufacturing market. Increasing geriatric population and increasing the prevalence of diseases such as cancer are driving the growth of biologic contract manufacturing market. Production of biologics requires highly skilled professional and aseptic environment which will restrain the growth of this market. Beside that production of biologics are very complex and costly method which can again hamper the growth of this market.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2679

Biologics Contract Manufacturing Market: Segmentation

Based on product type biologics contract manufacturing market is segmented into following

  • Antisense

  • Cell Therapy

  • Gene Therapy

  • Growth Factors

  • Interferon’s

  • Monoclonal Antibodies

  • Recombinant Hormones

  • RNA Interference

  • Vaccines

  • Others

Based on indication biologics contract manufacturing market is segmented into following

  • Autoimmune Disorders

  • Blood Disorders

  • Cancer

  • Cardiovascular Diseases

  • Digestive Disorder

  • Eye Condition

  • Genetic Disorder

  • Infectious Diseases

  • Musculoskeletal Disorders

  • Neurologic Disorders

  • Respiratory Disorders

  • Skin Diseases

  • Others

Based on geography biologics contract manufacturing market is segmented into following

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • Asia Pacific excluding Japan

  • Japan

  • Middle East and Africa

Biologics Contract Manufacturing Market: Overview

Biologics contract manufacturing is expected to show significant growth over the forecast period. Biologics cover around 10-15% of revenue from overall revenue generated by leading pharmaceutical companies. Biologics contract manufacturing market is expected to show double growth in every five years. This market is growing because of traditional pharmaceutical companies are unable for meet the need required for the production of biologics, besides that they are also the lack of skilled professional. Biologic contract manufacturing market can be classified by product type and indication. On the basis on product type biologic contract manufacturing market is classified as antisense, gene therapy, cell therapy, growth factors, interferon’s, monoclonal antibodies, recombinant hormones, RNA interference, vaccines and others. From all product type monoclonal antibodies is expected to dominate the biologic contract manufacturing market.

Biologics Contract Manufacturing Market: Regional Overview

Region-wise contract manufacturing market is classified as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America is expected to dominate the biologics contract manufacturing due to rise in FDA approval in last decade. Western Europe and Asia-Pacific then follow this market. Western Europe is projected to show subsequent growth due to the high availability of skilled professional for the production of biologics. Asia-Pacific region is expected to show the fastest growth over the forecast period owing to rise in the number of CMO’s.

Request to View TOC@ https://www.futuremarketinsights.com/toc/rep-gb-2679

Biologics Contract Manufacturing Market: Key Players

Some of the key players in biologics contract manufacturing market are Boehringer Ingelheim, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Rentschler Biotechnologie GmbH, Celonic AG, AutekBio Co. Ltd., WuXiAppTec, Kemwell Biopharma, Shasun Pharma, Intas Pharmaceuticals, Syngene, Piramal Pharma Solutions, AAIPharma Services, Alpax Pharmaceuticals, Cantab Biopharmaceuticals Ltd, 3P Biopharmaceuticals, and BIBITEC GmbH.

About the Author

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. Fmi is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

Rate this Article
Leave a Comment
Author Thumbnail
I Agree:
Comment 
Pictures
Author: Amir Shaikh

Amir Shaikh

Member since: Jun 21, 2018
Published articles: 98

Related Articles